All In Biotech

Drug Trial Radar · NCT01070836

JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab

JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2

Last checked: Nov 20, 2026Latest source record: Sep 29, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35,895

Actual

Start

Mar 2010

Primary completion

Nov 2015

Study completion Nov 2015

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Feb 18, 2010

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to demonstrate that the incidence of progressive multifocal Leukoencephalopathy (PML) in natalizumab-treated participants who do not have detectable antibodies to John Cunningham virus (JCV) (antibody negative) is lower than in participants who have detectable antibodies to JCV (antibody positive). The secondary objectives of this study are to: Estimate the incidence of PML in natalizumab-treated participants who are anti-JCV antibody negative and anti-JCV antibody positive, based on a meta-analysis of data obtained from this study and other data sources; Define the prevalence of anti-JCV antibody in relapsing multiple sclerosis (MS) participants receiving natalizumab within the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program; Determine changes in anti-JCV antibody status over time.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • natalizumabDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Demonstrate that the incidence of PML in natalizumab-treated participants who do not have detectable antibodies to JC virus (JCV) (antibody negative) is lower than in patents who have detectable antibodies to JCV (antibody positive)Time frame: Up to 4 years

Locations

478 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Cullman, Alabama

  • Research Site

    Tucaloosa, Alabama

  • Research Site

    Anchorage, Alaska

  • Research Site

    Flagstaff, Arizona

  • Research Site

    Gilbert, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Fayetteville, Arkansas

  • Research Site

    Little Rock, Arkansas

  • Research Site

    Sherwood, Arkansas

  • Research Site

    Auburn, California

  • Research Site

    Berkeley, California

  • Research Site

    Carmel, California

  • Research Site

    Carmichael, California

  • Research Site

    Fountain Valley, California

  • Research Site

    Fresno, California

  • Research Site

    Fresno, California

  • Research Site

    Fullerton, California

  • Research Site

    La Jolla, California

  • Research Site

    Loma Linda, California

  • Research Site

    Los Alamitos, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Marina del Rey, California

  • Research Site

    Modesto, California

  • Research Site

    Newport Beach, California

  • Research Site

    Northridge, California

  • Research Site

    Palo Alto, California

  • Research Site

    Pasadena, California

  • Research Site

    Pasadena, California

  • Research Site

    Redding, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

Showing 40 of 478 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.